Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420836 | 0.83 | S100A4 (0.37) | MAPTALDH1A1KDM4EPBRM1MAOB | |
| SCHEMBL68563 | 0.81 | KDM4E (0.48) | MAPTALDH1A1KDM4ELMNAMAOA | |
| SCHEMBL4255191 | 0.80 | TDP2 (0.36) | MAPTALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL68066 | 0.80 | VHL (0.50) | MAPTALDH1A1KDM4EMAOAMAOB | |
| SCHEMBL12471284 | 0.80 | MEN1 (0.47) | MAPTALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL10382360 | 0.80 | HTT (0.42) | ALDH1A1LMNACA1CA2CA7 | |
| SCHEMBL1140756 | 0.79 | ALDH1A1 (0.47) | MAPTALDH1A1KDM4ELMNAMAOA | |
| SCHEMBL14145176 | 0.76 | KDM4E (0.33) | ALDH1A1KDM4ELMNA | |
| SCHEMBL1140750 | 0.76 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL12470715 | 0.76 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4EMAOACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026778-B1 | RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND/OR RADIATION THERAPY SIDE EFFECTS | IO THERAPEUTICS LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| EP-2053095-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORP (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| US-9271946-B2 | Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects | Io Therapeutics, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2228417-B1 | Ink composition and inkjet recording method | FUJIFILM CORP (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2053095-B1 | Ink composition and inkjet recording method using the same | FUJIFILM CORP (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-8129447-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129447-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20030144256-A1 | Male anti-fertility agents | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | disclosed |
| US-6521641-B1 | Retinoic acid receptor antagonists or inverse agonists; reversibly inhibiting or preventing spermatogenesis | ALLERGAN, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020193403-A1 | Methods of treating hyperlipidemia | ALLERGAN SALES, INC. (US) | 2002-12-19 | — | — | US | disclosed |
| EP-1119350-A2 | RAR ANTAGONISTS AS MALE ANTI-FERTILITY AGENTS | Allergan Sales, Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000019990-A2 | RAR ANTAGONISTS AS MALE ANTI-FERTILITY AGENTS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5958954-A | 2,2-DIALKYL-4-ARYL-SUBSTITUTED BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES | ALLERGAN SALES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193403-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | MAPT 4680/4885ALDH1A1 803/4885KDM4E 2710/4885 |
| US-20030144256-A1 | Male anti-fertility agents | NASP, ALPG, MAN2B2 | MAPT 4505/4885ALDH1A1 813/4885KDM4E 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.